Advanced Cholangiocarcinoma

Oncology
8
Pipeline Programs
5
Companies
8
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Monoclonal Antibody
125%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

Taiho Oncology
LYTGOBIApproved
futibatinib
Taiho Oncology
oral2022

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Taiho Oncology
Taiho OncologyNJ - Princeton
3 programs
1
1
1
FutibatinibPhase 3Small Molecule1 trial
TAS-120Phase 21 trial
TAS-120N/A1 trial
Active Trials
NCT04507503Approved For Marketing
NCT05727176RecruitingEst. Dec 2026
NCT04093362TerminatedEst. Apr 2024
BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
2 programs
1
1
BGJ398Phase 31 trial
BGJ398Phase 21 trial
Active Trials
NCT02150967Terminated143Est. Feb 2022
NCT03773302Terminated48Est. Mar 2023
M&
Merck & Co.RAHWAY, NJ
1 program
1
PembrolizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02982720Terminated4Est. Feb 2018
CT
1 program
1
AnlotinibPhase 1/2Small Molecule1 trial
Active Trials
NCT03996408UnknownEst. Mar 2022
Genentech
GenentechCA - Oceanside
1 program
1
PemigatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT06439485Recruiting25Est. Feb 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Taiho OncologyFutibatinib
BridgeBio PharmaBGJ398
Taiho OncologyTAS-120
Merck & Co.Pembrolizumab
BridgeBio PharmaBGJ398
GenentechPemigatinib
Chia Tai TianQing Pharmaceutical GroupAnlotinib

Clinical Trials (8)

Total enrollment: 220 patients across 8 trials

NCT04093362Taiho OncologyFutibatinib

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Start: Jan 2021Est. completion: Apr 2024
Phase 3Terminated
NCT03773302BridgeBio PharmaBGJ398

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Start: Dec 2019Est. completion: Mar 202348 patients
Phase 3Terminated
NCT05727176Taiho OncologyTAS-120

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Start: Jul 2023Est. completion: Dec 2026
Phase 2Recruiting
NCT02982720Merck & Co.Pembrolizumab

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Start: Jul 2017Est. completion: Feb 20184 patients
Phase 2Terminated
NCT02150967BridgeBio PharmaBGJ398

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Start: Jul 2014Est. completion: Feb 2022143 patients
Phase 2Terminated
NCT06439485GenentechPemigatinib

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Start: Nov 2024Est. completion: Feb 203025 patients
Phase 1/2Recruiting
NCT03996408Chia Tai TianQing Pharmaceutical GroupAnlotinib

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Start: Jun 2019Est. completion: Mar 2022
Phase 1/2Unknown
NCT04507503Taiho OncologyTAS-120

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

N/AApproved For Marketing

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 220 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)